1996
DOI: 10.1038/bjc.1996.633
|View full text |Cite
|
Sign up to set email alerts
|

MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up

Abstract: Summary Alteration in MHC class I expression may be used by cancer cells to avoid immune destruction. Much experimental evidence supports this idea, although survival studies are very scarce. To investigate whether the presence or absence of HLA-A, -B and -C antigens in laryngeal carcinoma influences survival, a series of 60 primary laryngeal tumours treated surgically and normal tissues were evaluated in frozen sections for the expression of MHC class I antigens and tumour-infiltrating leucocytes (CD3, CD4, C… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
12
1

Year Published

1998
1998
2019
2019

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(13 citation statements)
references
References 35 publications
(13 reference statements)
0
12
1
Order By: Relevance
“…This frequency is similar to that found in 70 maxillary sinus SCC lesions (11), but is higher than that previously described in laryngeal SCC lesions, which range between 29% and 66% (6,(12)(13)(14)(15)(16). Our study differs from the other published Figure 4.…”
Section: Discussioncontrasting
confidence: 57%
See 1 more Smart Citation
“…This frequency is similar to that found in 70 maxillary sinus SCC lesions (11), but is higher than that previously described in laryngeal SCC lesions, which range between 29% and 66% (6,(12)(13)(14)(15)(16). Our study differs from the other published Figure 4.…”
Section: Discussioncontrasting
confidence: 57%
“…Laryngeal SCC is no exception to this finding. The frequency of HLA class I antigen defects in laryngeal SCC lesions reported in the literature ranges between 29% and 66% (6,(12)(13)(14)(15)(16). Because of the role of HLA class I antigens in the presentation of tumor antigen (TA)-derived peptides to the host's immune system, these defects are likely to have a negative effect on the clinical course of the disease and on the outcome of T cell-based immunotherapy.…”
Section: Introductionmentioning
confidence: 99%
“…(3). Such an immune escape mechanism has also been suggested for HNSCC cells and might be reflected by a low T cell infiltration of tumors or by inefficient activation and generation of HNSCC-associated antigenspecific CTL as described by several investigators (20,22,25). Restoration of antigen presentation by cytokine treatment and/or gene transfer of deficient APM component consequently renders cells sensitive to CTL-mediated lysis.…”
Section: Discussionmentioning
confidence: 99%
“…In melanoma, breast, lung, and cervical carcinoma, the lack of HLA class I antigen surface expression and/or TAP expression was reported to be associated with poor tumor differentiation, increased frequency of aneuploidy as well as reduced survival rate (37,38,45,46). Conflicting information is available about the association between HLA class I antigen down-regulation and patients' survival in HNSCC patients (25,26,47). Our results are in accordance with those reported by one of the authors (26) showing a significant correlation between the survival time and a loss or down-regulation of APM components in primary maxillary sinus squamous cell carcinoma lesions.…”
Section: Discussionmentioning
confidence: 99%
“…Down-regulation of HLA-I has been reported in a variety of malignancies (Esteban et al, 1996), including a significant percentage of colorectal cancers and its precursor adenomas (Cordon et al, 1991;Garrido et al, 1993;Lopez-Nevot et al, 1989;Moller et al, 1991b;Momburg et al, 1986;Tsioulias et al, 1993) and may result in a worse clinical outcome. This correlation has indeed been observed in a number of malignancies, such as breast cancer (Concha et al, 1991), melanoma (van Duinen et al, 1988), and laryngeal carcinoma (Esteban et al, 1996) but not for colorectal cancer (Cordon et al, 1991;Lopez-Nevot et al, 1989;Moller et al, 1991b;Momburg et al, 1986;Stein et al, 1988). Immunohistochemical studies on HLA-I expression in (colorectal) cancer most com-monly investigated the expression of the entire HLA-ABC/␤2m complex using the antibody W6/32.…”
mentioning
confidence: 99%